Thyrocare®

Think Thyroid. Think Thyrocare.

June 13, 2019

The National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051

The Bombay Stock Exchange Ltd
Phiroze Jeejeeboy Towers
Dalal Street,
Mumbai- 400 001

Dear Sirs,

Sub: Outcome of Board Meeting held on 13-06-2019.

--o--

Please refer to our letter dated 20-05-2019, wherein we had intimated that at the Board Meeting held on 18-05-2019, when the Auditors pointed out the impairment of investment in Nueclear Healthcare Limited (NHL), the wholly owned subsidiary, Dr. A. Velumani, Chairman, Managing Director & CEO had offered to buy the entire shareholding of the Company in NHL at the current investment value of Rs. 194.67 crores to ensure that there is no loss to the public shareholders.

The above offer was discussed today at the meeting of the Audit Committee and later at the Board Meeting.

Both the Audit Committee and the Board of Directors have unanimously decided that the Company has to determine whether it would be beneficial for the Company to hive off the subsidiary or retain it, and for this purpose, it would be advisable to obtain one more valuation report to ensure that the valuation of the subsidiary has been correctly ascertained. The Committee decided to appoint a SEBI approved merchant banker to submit a valuation report, within the shortest possible time, and then take a decision.

None of the Promoter-directors were present during the discussions.

Yours Faithfully,
For **Thyrocare Technologies Limited,**

THYROCARE TECHNOLOGIES LIMITED

Ramjee Dorai
Company Secretary and Compliance Officer